Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry

References

• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-49; PMID:19474385; http://dx.doi.org/10.3322/caac.20006
   PubMed Web of Science ®Google Scholar
• Kalimutho M, Parsons K, Mittal D, Lopez JA, Srihari S, Khanna KK. Targeted therapies for triple-negative breast cancer: Combating a stubborn disease. Trends Pharmacol Sci 2015; 36:822-46; PMID:26538316; http://dx.doi.org/10.1016/j.tips.2015.08.009
   PubMed Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-52; PMID:10963602; http://dx.doi.org/10.1038/35021093
   PubMed Web of Science ®Google Scholar
• Chacon RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res 2010; 12(2):S3; PMID:21050424; http://dx.doi.org/10.1186/bcr2574
   PubMedGoogle Scholar
• Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13:4429-34; PMID:17671126; http://dx.doi.org/10.1158/1078-0432.CCR-06-3045
   PubMed Web of Science ®Google Scholar
• Stoeck A, Lejnine S, Truong A, Pan L, Wang H, Zang C, Yuan J, Ware C, MacLean J, Garrett-Engele PW, et al. Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma. Cancer Discov 2014; 4:1154-67; PMID:25104330; http://dx.doi.org/10.1158/2159-8290.CD-13-0830
   PubMed Web of Science ®Google Scholar
• Ibrahim YH, Garcia-Garcia C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2012; 2:1036-47; PMID:22915752; http://dx.doi.org/10.1158/2159-8290.CD-11-0348
   PubMed Web of Science ®Google Scholar
• Dieras V, Campone M, Yardley DA, Romieu G, Valero V, Isakoff SJ, Koeppen H, Wilson TR, Xiao Y, Shames DS, et al. Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer. Ann Oncol 2015; 26:1904-10; PMID:26202594; http://dx.doi.org/10.1093/annonc/mdv263
   PubMed Web of Science ®Google Scholar
• Curigliano G, Pivot X, Cortes J, Elias A, Cesari R, Khosravan R, Collier M, Huang X, Cataruozolo PE, Kern KA, et al. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. Breast 2013; 22:650-6; PMID:23958375; http://dx.doi.org/10.1016/j.breast.2013.07.037
   PubMed Web of Science ®Google Scholar
• Yardley DA, Shipley DL, Peacock NW, Shastry M, Midha R, Priego VM, Hainsworth JD. Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer. Breast Cancer Res Treat 2015; 152:557-67; PMID:26155975; http://dx.doi.org/10.1007/s10549-015-3482-4
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50; PMID:17167137; http://dx.doi.org/10.1056/NEJMoa061884
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010; 28:2137-43; PMID:20368558; http://dx.doi.org/10.1200/JCO.2009.26.5561
   PubMed Web of Science ®Google Scholar
• Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015; 33:13-21; PMID:25092775; http://dx.doi.org/10.1200/JCO.2014.57.0572
   PubMed Web of Science ®Google Scholar
• Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-31; PMID:19249680; http://dx.doi.org/10.1016/j.ccr.2009.01.027
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhang D, Sun B. Vasculogenic mimicry: current status and future prospects. Cancer Lett 2007; 254:157-64; PMID:17306454; http://dx.doi.org/10.1016/j.canlet.2006.12.036
   PubMed Web of Science ®Google Scholar
• Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA, Schatteman GC, Seftor RE. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci U S A 2001; 98:8018-23; PMID:11416160; http://dx.doi.org/10.1073/pnas.131209798
   PubMed Web of Science ®Google Scholar
• Zhang S, Guo H, Zhang D, Zhang W, Zhao X, Ren Z, Sun B. Microcirculation patterns in different stages of melanoma growth. Oncol Rep 2006; 15:15-20; PMID:16328029; http://dx.doi.org/10.3892/or.15.1.15
   PubMed Web of Science ®Google Scholar
• Hess AR, Seftor EA, Gardner LM, Carles-Kinch K, Schneider GB, Seftor RE, Kinch MS, Hendrix MJ. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res 2001; 61:3250-5; PMID:11309274; http://cancerres.aacrjournals.org/content/61/8/3250
   PubMed Web of Science ®Google Scholar
• Sun B, Qie S, Zhang S, Sun T, Zhao X, Gao S, Ni C, Wang X, Liu Y, Zhang L. Role and mechanism of vasculogenic mimicry in gastrointestinal stromal tumors. Hum Pathol 2008; 39:444-51; PMID:18261629; http://dx.doi.org/10.1016/j.humpath.2007.07.018
   PubMed Web of Science ®Google Scholar
• Shirakawa K, Kobayashi H, Sobajima J, Hashimoto D, Shimizu A, Wakasugi H. Inflammatory breast cancer: vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft model. Breast Cancer Res 2003; 5:136-9; PMID:12793894; http://dx.doi.org/10.1186/bcr585
   PubMed Web of Science ®Google Scholar
• Sun T, Zhao N, Zhao XL, Gu Q, Zhang SW, Che N, Wang XH, Du J, Liu YX, Sun BC. Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatology 2010; 51:545-56; PMID:19957372; http://dx.doi.org/10.1002/hep.23311
   PubMed Web of Science ®Google Scholar
• Sun T, Sun BC, Zhao XL, Zhao N, Dong XY, Che N, Yao Z, Ma YM, Gu Q, Zong WK, et al. Promotion of tumor cell metastasis and vasculogenic mimicry by way of transcription coactivation by Bcl-2 and Twist1: a study of hepatocellular carcinoma. Hepatology 2011; 54:1690-706; PMID:21748764; http://dx.doi.org/10.1002/hep.24543
   PubMed Web of Science ®Google Scholar
• Liu X, Wang X, Du W, Chen L, Wang G, Cui Y, Liu Y, Dou Z, Wang H, Zhang P, et al. Suppressor of fused (Sufu) represses Gli1 transcription and nuclear accumulation, inhibits glioma cell proliferation, invasion and vasculogenic mimicry, improving glioma chemo-sensitivity and prognosis. Oncotarget 2014; 5:11681-94; PMID:25373737; http://dx.doi.org/10.18632/oncotarget.2585
   PubMed Web of Science ®Google Scholar
• Orecchia P, Conte R, Balza E, Pietra G, Mingari MC, Carnemolla B. Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts. Oncotarget 2015; 6:37426-42; PMID:26460958; http://dx.doi.org/10.18632/oncotarget.6055
   PubMed Web of Science ®Google Scholar
• Zhang D, Sun B, Zhao X, Ma Y, Ji R, Gu Q, Dong X, Li J, Liu F, Jia X, et al. Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer. Mol Cancer 2014; 13:207; PMID:25200065; http://dx.doi.org/10.1186/1476-4598-13-207
   PubMed Web of Science ®Google Scholar
• Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, Rathmell WK, Generali D, Nagaraju GP, El-Rayes B, Ribatti D, et al. Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol 2015; 35:S224-43; PMID:25600295; http://dx.doi.org/10.1016/j.semcancer.2015.01.001
   PubMed Web of Science ®Google Scholar
• Vasudev NS, Goh V, Juttla JK, Thompson VL, Larkin JM, Gore M, Nathan PD, Reynolds AR. Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy. Br J Cancer 2013; 109:1230-42; PMID:23922108; http://dx.doi.org/10.1038/bjc.2013.429
   PubMed Web of Science ®Google Scholar
• Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, Clouthier SG, Wicha MS. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A 2012; 109:2784-9; PMID:22308314; http://dx.doi.org/10.1073/pnas.1018866109
   PubMed Web of Science ®Google Scholar
• Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD, Engh J, Iwama T, Kunisada T, Kassam AB, et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 2009; 28:3949-59; PMID:19718046; http://dx.doi.org/10.1038/onc.2009.252
   PubMed Web of Science ®Google Scholar
• McIntyre A, Harris AL. Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality. EMBO Mol Med 2015; 7:368-79; PMID:25700172; http://dx.doi.org/10.15252/emmm.201404271
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8:592-603; PMID:18650835; http://dx.doi.org/10.1038/nrc2442
   PubMed Web of Science ®Google Scholar
• Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 2014; 17:471-94; PMID:24482243; http://dx.doi.org/10.1007/s10456-014-9420-y
   PubMed Web of Science ®Google Scholar
• Seftor RE, Hess AR, Seftor EA, Kirschmann DA, Hardy KM, Margaryan NV, Hendrix MJ. Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am J Pathol 2012; 181:1115-25; PMID:22944600; http://dx.doi.org/10.1016/j.ajpath.2012.07.013
   PubMed Web of Science ®Google Scholar
• Singleton DC, Rouhi P, Zois CE, Haider S, Li JL, Kessler BM, Cao Y, Harris AL. Hypoxic regulation of RIOK3 is a major mechanism for cancer cell invasion and metastasis. Oncogene 2015; 34:4713-22; PMID:25486436; http://dx.doi.org/10.1038/onc.2014.396
   PubMed Web of Science ®Google Scholar
• Chaturvedi P, Gilkes DM, Takano N, Semenza GL. Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment. Proc Natl Acad Sci U S A 2014; 111:E2120-9; PMID:24799675; http://dx.doi.org/10.1073/pnas.1406655111
   PubMedGoogle Scholar
• Hwang-Verslues WW, Chang PH, Jeng YM, Kuo WH, Chiang PH, Chang YC, Hsieh TH, Su FY, Lin LC, Abbondante S, et al. Loss of corepressor PER2 under hypoxia up-regulates OCT1-mediated EMT gene expression and enhances tumor malignancy. Proc Natl Acad Sci U S A 2013; 110:12331-6; PMID:23836662; http://dx.doi.org/10.1073/pnas.1222684110
   PubMed Web of Science ®Google Scholar
• Kirschmann DA, Seftor EA, Hardy KM, Seftor RE, Hendrix MJ. Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin Cancer Res 2012; 18:2726-32; PMID:22474319; http://dx.doi.org/10.1158/1078-0432.CCR-11-3237
   PubMed Web of Science ®Google Scholar
• Seftor RE, Seftor EA, Koshikawa N, Meltzer PS, Gardner LM, Bilban M, Stetler-Stevenson WG, Quaranta V, Hendrix MJ. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 2001; 61:6322-7; PMID:11522618; http://cancerres.aacrjournals.org/content/61/17/6322.long
   PubMed Web of Science ®Google Scholar
• Wang H, Sun W, Zhang WZ, Ge CY, Zhang JT, Liu ZY, Fan YZ. Inhibition of tumor vasculogenic mimicry and prolongation of host survival in highly aggressive gallbladder cancers by norcantharidin via blocking the ephrin type a receptor 2/focal adhesion kinase/paxillin signaling pathway. PLoS One 2014; 9:e96982; PMID:24811250; http://dx.doi.org/10.1371/journal.pone.0096982
   PubMedGoogle Scholar
• Sun D, Sun B, Liu T, Zhao X, Che N, Gu Q, Dong X, Yao Z, Li R, Li J, et al. Slug promoted vasculogenic mimicry in hepatocellular carcinoma. J Cell Mol Med 2013; 17:1038-47; PMID:23815612; http://dx.doi.org/10.1111/jcmm.12087
   PubMed Web of Science ®Google Scholar
• Du J, Sun B, Zhao X, Gu Q, Dong X, Mo J, Sun T, Wang J, Sun R, Liu Y. Hypoxia promotes vasculogenic mimicry formation by inducing epithelial-mesenchymal transition in ovarian carcinoma. Gynecol Oncol 2014; 133:575-83; PMID:24589413; http://dx.doi.org/10.1016/j.ygyno.2014.02.034
   PubMed Web of Science ®Google Scholar
• Qi H, Sun B, Zhao X, Du J, Gu Q, Liu Y, Cheng R, Dong X. Wnt5a promotes vasculogenic mimicry and epithelial-mesenchymal transition via protein kinase Calpha in epithelial ovarian cancer. Oncol Rep 2014; 32:771-9; PMID:24898696; http://dx.doi.org/10.3892/or.2014.3229
   PubMed Web of Science ®Google Scholar
• Sun B, Zhang S, Zhang D, Li Y, Zhao X, Luo Y, Guo Y. Identification of metastasis-related proteins and their clinical relevance to triple-negative human breast cancer. Clin Cancer Res 2008; 14:7050-9; PMID:18981002; http://dx.doi.org/10.1158/1078-0432.CCR-08-0520
   PubMed Web of Science ®Google Scholar